Jenburkt Pharmaceuticals growth over the years

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr3 yr
Revenue+11.2%+7.3%
EBITDA+8.0%+13.1%
Net Income+8.4%+12.2%
Total Assets+15.2%+16.8%
Free Cash Flow−5.0%+15.9%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

JENBURPH₹875.95

Jenburkt Pharmaceuticals Limited

· Pharma & Health
₹ CrorePeersBPLPHARMAKPLMAKERSLNOVARTINDPARNAXLABSGRLSHUKRAPHARSUNLOC
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
3Y
CAGR
Revenue+11.2+7.3
EBITDA+8.0+13.1
Net Income+8.4+12.2
Total Assets+15.2+16.8
Free Cash Flow-5.0+15.9
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.